JP2024525184A - Ｂ型肝炎ウイルスｐｒｅＳ１抗原の肝細胞受容体結合部位に特異的に結合するヒト抗体及びその用途 - Google Patents

Ｂ型肝炎ウイルスｐｒｅＳ１抗原の肝細胞受容体結合部位に特異的に結合するヒト抗体及びその用途 Download PDF

Info

Publication number
JP2024525184A
JP2024525184A JP2023577967A JP2023577967A JP2024525184A JP 2024525184 A JP2024525184 A JP 2024525184A JP 2023577967 A JP2023577967 A JP 2023577967A JP 2023577967 A JP2023577967 A JP 2023577967A JP 2024525184 A JP2024525184 A JP 2024525184A
Authority
JP
Japan
Prior art keywords
antibody
seq
pres1
hbv
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023577967A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525184A5 (enExample
Inventor
ジョン ホン ヒョ
ジョウ キョンヒ
ホン ジス
ジン チェ ヨン
リー ジウ
Original Assignee
アピットバイオ， インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アピットバイオ， インク． filed Critical アピットバイオ， インク．
Publication of JP2024525184A publication Critical patent/JP2024525184A/ja
Publication of JP2024525184A5 publication Critical patent/JP2024525184A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G01N33/5764—Hepatitis B surface antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023577967A 2021-06-15 2022-05-30 Ｂ型肝炎ウイルスｐｒｅＳ１抗原の肝細胞受容体結合部位に特異的に結合するヒト抗体及びその用途 Pending JP2024525184A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2021-0077615 2021-06-15
KR20210077615 2021-06-15
KR10-2021-0093625 2021-07-16
KR20210093625 2021-07-16
PCT/KR2022/007679 WO2022265264A1 (ko) 2021-06-15 2022-05-30 B형 간염바이러스 pres1항원의 간세포 수용체 결합부위에 특이적으로 결합하는 인간 항체 및 이의 용도

Publications (2)

Publication Number Publication Date
JP2024525184A true JP2024525184A (ja) 2024-07-10
JP2024525184A5 JP2024525184A5 (enExample) 2025-04-14

Family

ID=84527149

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023577967A Pending JP2024525184A (ja) 2021-06-15 2022-05-30 Ｂ型肝炎ウイルスｐｒｅＳ１抗原の肝細胞受容体結合部位に特異的に結合するヒト抗体及びその用途

Country Status (5)

Country Link
US (1) US20240254200A1 (enExample)
EP (1) EP4357360A4 (enExample)
JP (1) JP2024525184A (enExample)
KR (2) KR102680147B1 (enExample)
WO (1) WO2022265264A1 (enExample)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100250831B1 (ko) * 1997-07-02 2000-04-01 박호군 비형 간염 바이러스의 표면 항원 프리-에스1 에피토프를 인식하는 생쥐 단일클론 항체의 가변 영역,이를 암호하는 유전자 및 그의 염기 서열
JP2018519804A (ja) * 2015-05-22 2018-07-26 フアフイ ヘルス リミテッドＨｕａｈｕｉ Ｈｅａｌｔｈ Ｌｔｄ． 抗Ｐｒｅ−Ｓ１ ＨＢＶ抗体
JP2018531911A (ja) * 2015-09-05 2018-11-01 ヴィラヴァックス アーゲー 融合タンパク質
CN110003326A (zh) * 2019-04-15 2019-07-12 郑州伊美诺生物技术有限公司 乙肝病毒前s1蛋白特异性抗体的制备方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016154593A1 (en) * 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
EP3181146A1 (en) * 2015-12-16 2017-06-21 Ruprecht-Karls-Universität Heidelberg Cyclic ntcp-targeting peptides and their uses as entry inhibitors
CN111542340B (zh) * 2017-11-16 2023-12-19 华盛顿大学 治疗性乙型肝炎病毒(hbv)疫苗
KR20200092539A (ko) * 2019-01-25 2020-08-04 진원생명과학 주식회사 B형 간염 치료 및 예방용 항체

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100250831B1 (ko) * 1997-07-02 2000-04-01 박호군 비형 간염 바이러스의 표면 항원 프리-에스1 에피토프를 인식하는 생쥐 단일클론 항체의 가변 영역,이를 암호하는 유전자 및 그의 염기 서열
JP2018519804A (ja) * 2015-05-22 2018-07-26 フアフイ ヘルス リミテッドＨｕａｈｕｉ Ｈｅａｌｔｈ Ｌｔｄ． 抗Ｐｒｅ−Ｓ１ ＨＢＶ抗体
JP2018531911A (ja) * 2015-09-05 2018-11-01 ヴィラヴァックス アーゲー 融合タンパク質
CN110003326A (zh) * 2019-04-15 2019-07-12 郑州伊美诺生物技术有限公司 乙肝病毒前s1蛋白特异性抗体的制备方法及其应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
J. MICROBIOL. BIOTECHNOL., vol. 27(7), JPN6026011029, 2017, pages 1336 - 1344, ISSN: 0005822666 *
J. MICROBIOL. BIOTECHNOL., vol. 28(8), JPN6026011026, 2018, pages 1376 - 1383, ISSN: 0005822663 *
J. VIROL., vol. 95, no. 5, JPN6026011028, February 2021 (2021-02-01), pages 01680 - 20, ISSN: 0005822665 *
VACCINES, vol. 9, JPN6026011027, 7 July 2021 (2021-07-07), pages 754, ISSN: 0005822664 *
VIROLOGY, vol. 270, JPN6026011030, 2000, pages 9 - 16, ISSN: 0005822667 *

Also Published As

Publication number Publication date
US20240254200A1 (en) 2024-08-01
WO2022265264A1 (ko) 2022-12-22
EP4357360A1 (en) 2024-04-24
KR20220168148A (ko) 2022-12-22
EP4357360A4 (en) 2025-07-30
KR20240029010A (ko) 2024-03-05
KR102680147B1 (ko) 2024-07-03

Similar Documents

Publication Publication Date Title
JP7700190B2 (ja) Ｉｌｔ７結合分子及びその使用方法
CA2734645A1 (en) Engineered anti-il-13 antibodies, compositions, methods and uses
CA3209136A1 (en) Antibodies targeting the spike protein of coronaviruses
US9403909B2 (en) Anti-MST1R antibodies and uses thereof
JP2024505674A (ja) 抗ｉｌ１ｒａｐ抗体
US12215168B2 (en) Anti-A2AP antibodies and uses thereof
WO2021105669A1 (en) Antibodies
JP2022550121A (ja) Ｌｉｆに特異的な結合分子及びその使用
KR20220054080A (ko) SARS-CoV-2 스파이크 단백질에 특이적으로 결합하는 항체 및 이의 용도
KR102680147B1 (ko) B형 간염바이러스 preS1항원의 간세포 수용체 결합부위에 특이적으로 결합하는 인간 항체 및 이의 용도
JP7599186B2 (ja) コロナウイルススパイクタンパク質に特異的な抗体及びその用途
CN117858896A (zh) 特异性结合乙型肝炎病毒preS1抗原肝细胞受体结合基序的人抗体及其用途
RU2844816C1 (ru) Новые антитела против a2ap и их применение
US20170183401A1 (en) Hypoglycemic agent containing anti-ang2 antibody
JP2023519007A (ja) Ａｒｅｇに対する抗体及びその用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250404

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250404

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260324